Drug eluting stents in 2005

Heart

Volumn 91, Issue SUPPL. 3, 2005, Pages

  Gershlick, Anthony H ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 578; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN; RAPAMYCIN DERIVATIVE;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG ELUTING STENT; HUMAN; PACLITAXEL ELUTING STENT; PRIORITY JOURNAL; REVIEW; SAFETY; SIROLIMUS ELUTING STENT; TECHNIQUE; TREATMENT OUTCOME;

CORONARY RESTENOSIS; DRUG IMPLANTS; EQUIPMENT FAILURE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; SIROLIMUS; STENTS;

EID: 20044370346     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.060277     Document Type: Review

References (12)

1. Serruys PW, Unger F, van Hout BA. The ARTS study (arterial revascularization therapies study). Semin Interv Cardiol 1999;4:209-19.
2. SOS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the stent or surgery trial): a randomised controlled trial. Lancet 2002;360:965-70.
3. Morice MC, Serruys PW, Sousa JE. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
4. Moses JW, Leon MB, Popma JJ. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
5. Schampaert E, Cohen EA, Schluter M. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
6. Schofer J, Schluter M, Gershlick AH. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
7. Axel DI, Kunert W, Goggelmann C. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
8. Gershlick A, De Scheerder I, Chevalier B. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaluation of paclitaxel eluting stent (ELUTES) trial. Circulation 2004;109:487-93.
9. Hong MK, Mintz GS, Lee CW. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian paclitaxel-eluting stent clinical trial (ASPET). Circulation 2003;107:517-20.
10. Colombo A, Drzewiecki J, Banning A. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
11. Buellesfeld L, Grube E. ABT-578-eluting stents: the promising successor of sirolimus- and poclitaxel-eluting stent concepts? Herz 2004;29:167-70.
12. Formica RN Jr, Lorber KM, Friedman AL. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004;36(2 suppl):S495-9.